- Home
- AQB vs CLGN Comparison
AQB vs CLGN Comparison
Compare AQB & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | CLGN |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.2M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AQB | CLGN |
|---|---|---|
| Price | $0.92 | $4.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 61.0K | 36.7K |
| Earning Date | 11-06-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,472,659.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $400.00 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.26 |
| 52 Week High | $6.25 | $4.78 |
Technical Indicators
Market Signals| Indicator | AQB | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 54.02 |
| Support Level | $0.86 | $0.34 |
| Resistance Level | $1.02 | $4.64 |
| Average True Range (ATR) | 0.10 | 0.38 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 5.58 | 44.92 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.